Payment overview · 2025
General Payments
$1,434.28
56 reported records · 12 companies
Healthcare provider profile · identity verified
James M Lawrence, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · MOBILE, AL · NPI 1669657896
Verified facts
What the public records show
CMS Open Payments records show James M Lawrence, MD received $1,434.28 in general payments during 2025 across 56 reported records.
GlaxoSmithKline, LLC. accounted for 23.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Benlysta, Lupkynis, Ofev, Rinvoq.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Rinvoq by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Otezla by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
Aurinia Pharma U.S., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUPKYNIS as an associated drug or biological on 7773 records involving 3649 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lupkynis by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OFEV as an associated drug or biological on 14236 records involving 6873 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Ofev by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BENLYSTA as an associated drug or biological on 19884 records involving 5034 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Benlysta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $336.65 | 23.5% | 7 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $212.99 | 14.8% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $202.08 | 14.1% | 12 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $176.81 | 12.3% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $124.05 | 8.7% | 5 | 2025 |
| Aurinia Pharma U.S., Inc. | Unresolved — no canonical attribution shown | $114.92 | 8.0% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $105.94 | 7.4% | 5 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $69.91 | 4.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $35.96 | 2.5% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $21.58 | 1.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.92 | 1.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.47 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,434.28 | 56 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $256.40 | 6 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $212.99 | 11 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $176.81 | 4 | 2025 |
Source payment records
|
|||||
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $115.06 | 7 | 2025 |
Source payment records
|
|||||
| LUPKYNIS Normalized: lupkynis |
Drug | Aurinia Pharma U.S., Inc. | $114.92 | 5 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $105.94 | 5 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $87.02 | 5 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $84.46 | 4 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $69.91 | 2 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $18.07 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BENLYSTA benlysta |
2025 | Benlysta | 2024 | 78 | exact normalized | Medicare Part D |
| LUPKYNIS lupkynis |
2025 | Lupkynis | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OFEV ofev |
2025 | Ofev | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 110 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
110 | 17 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Aurinia Pharma U.S., Inc. Exact reporting entity; no affiliate inference |
2025 | LUPKYNIS open payments reported associated product |
CMS Open Payments — General Payments 7773 supporting records · 3649 recipient NPIs · example record 1249402448 |
Lupkynis · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OFEV open payments reported associated product |
CMS Open Payments — General Payments 14236 supporting records · 6873 recipient NPIs · example record 1221811762 |
Ofev · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | BENLYSTA open payments reported associated product |
CMS Open Payments — General Payments 19884 supporting records · 5034 recipient NPIs · example record 1190332353 |
Benlysta · 2024 Exact normalized brand match · 1 Part D row |
78 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 275 | 53 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 263 | 57 |
| Gabapentin | Gabapentin | 247 | 51 |
| Methotrexate | Methotrexate Sodium | 215 | 41 |
| Tramadol Hcl | Tramadol Hcl | 208 | 34 |
| Humira(Cf) Pen | Adalimumab | 204 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 175 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 168 | 29 |
| Prednisone | Prednisone | 154 | 42 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 152 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 150 | 42 |
| Pregabalin | Pregabalin | 140 | 25 |
| Leflunomide | Leflunomide | 111 | 41 |
| Rinvoq | Upadacitinib | 110 | 17 |
| Pentoxifylline | Pentoxifylline | 94 | 16 |
| Benlysta | Belimumab | 78 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 76 | 11 |
| Xeljanz | Tofacitinib Citrate | 70 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 12 |
| Topiramate | Topiramate | 68 | 18 |
| Clonazepam | Clonazepam | 67 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 61 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 58 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 56 | 13 |
| Buspirone Hcl | Buspirone Hcl | 55 | 17 |
| Diazepam | Diazepam | 54 | suppressed |
| Ibuprofen | Ibuprofen | 50 | 11 |
| Losartan Potassium | Losartan Potassium | 49 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 13 |
| Ozempic | Semaglutide | 48 | suppressed |
| Baclofen | Baclofen | 45 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 45 | suppressed |
| Omeprazole | Omeprazole | 43 | 14 |
| Dronabinol | Dronabinol | 42 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 41 | suppressed |
| Prolate | Oxycodone Hcl/Acetaminophen | 39 | suppressed |
| Lorazepam | Lorazepam | 38 | suppressed |
| Memantine Hcl | Memantine Hcl | 37 | 14 |
| Allopurinol | Allopurinol | 33 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 32 | suppressed |
| Meloxicam | Meloxicam | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Famotidine | Famotidine | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 22 | suppressed |
| Cosentyx Sensoready (2 Pens) | Secukinumab | 21 | suppressed |
| Enbrel Sureclick | Etanercept | 21 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 13 |
| Colchicine | Colchicine | 20 | suppressed |
| Ofev | Nintedanib Esylate | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Alprazolam | Alprazolam | 18 | suppressed |
| Piroxicam | Piroxicam | 18 | suppressed |
| Eliquis | Apixaban | 17 | suppressed |
| Potassium Chloride | Potassium Chloride | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Dupixent Pen | Dupilumab | 15 | suppressed |
| Furosemide | Furosemide | 15 | suppressed |
| Indomethacin | Indomethacin | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 14 | suppressed |
| Carvedilol | Carvedilol | 14 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 14 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 14 | suppressed |
| Xifaxan | Rifaximin | 14 | suppressed |
| Cyclosporine | Cyclosporine | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 13 | suppressed |
| Lupkynis | Voclosporin | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Otezla | Apremilast | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,434.28 · 56 records | GlaxoSmithKline, LLC. | ACTHAR, BENLYSTA, KRYSTEXXA, LUPKYNIS, OFEV, PURIFIED CORTROPHIN GEL, RINVOQ, SAPHNELO, SIMPONI ARIA, SKYRIZI, Sunosi, TAVNEOS, TREMFYA, The Cologuard Plus Collection Kit | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Benlysta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error